Watson Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for orlistat capsules approved and issued by the State Drug Administration. Both drugs are Class 4 and Class A non-prescription drugs, and the drug approval number is valid until October 12, 2031. This approval is conducive to enriching the company's metabolic disease product pipeline and providing a product foundation for expanding the out-of-hospital market. There is uncertainty about drug production and sales due to factors such as industry policies and market competition.

Watson Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for orlistat capsules approved and issued by the State Drug Administration. Both drugs are Class 4 and Class A non-prescription drugs, and the drug approval number is valid until October 12, 2031. This approval is conducive to enriching the company's metabolic disease product pipeline and providing a product foundation for expanding the out-of-hospital market. There is uncertainty about drug production and sales due to factors such as industry policies and market competition.